- Home
- TSLX vs RCKT Comparison
TSLX vs RCKT Comparison
Compare TSLX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSLX | RCKT |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 394.2M |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TSLX | RCKT |
|---|---|---|
| Price | $17.86 | $3.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $21.61 | ★ $29.73 |
| AVG Volume (30 Days) | 366.2K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 10.82% | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | 0.15 | ★ 0.66 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.20 | $64.28 |
| P/E Ratio | $121.27 | ★ $5.30 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.04 | $2.53 |
| 52 Week High | $23.56 | $5.45 |
Technical Indicators
Market Signals| Indicator | TSLX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 45.12 |
| Support Level | $17.42 | $3.36 |
| Resistance Level | $17.99 | $3.65 |
| Average True Range (ATR) | 0.37 | 0.20 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 11.43 | 27.52 |
Price Performance
Historical ComparisonAbout TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.